We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emerging role of 18F-FDG PET/CT in Castleman disease: a review.
- Authors
Koa, Benjamin; Borja, Austin J.; Aly, Mahmoud; Padmanabhan, Sayuri; Tran, Joseph; Zhang, Vincent; Rojulpote, Chaitanya; Pierson, Sheila K.; Tamakloe, Mark-Avery; Khor, Johnson S.; Werner, Thomas J.; Fajgenbaum, David C.; Alavi, Abass; Revheim, Mona-Elisabeth
- Abstract
Castleman disease (CD) describes a group of rare hematologic conditions involving lymphadenopathy with characteristic histopathology and a spectrum of clinical abnormalities. CD is divided into localized or unicentric CD (UCD) and multicentric CD (MCD) by imaging. MCD is further divided based on etiological driver into human herpesvirus-8-associated MCD, POEMS-associated MCD, and idiopathic MCD. There is notable heterogeneity across MCD, but increased level of pro-inflammatory cytokines, particularly interleukin-6, is an established disease driver in a portion of patients. FDG-PET/CT can help determine UCD versus MCD, evaluate for neoplastic conditions that can mimic MCD clinico-pathologically, and monitor therapy responses. CD requires more robust characterization, earlier diagnosis, and an accurate tool for both monitoring and treatment response evaluation; FDG-PET/CT is particularly suited for this. Moving forward, future prospective studies should further characterize the use of FDG-PET/CT in CD and specifically explore the utility of global disease assessment and dual time point imaging. Trial registration ClinicalTrials.gov, NCT02817997, Registered 29 June 2016, https://clinicaltrials.gov/ct2/show/NCT02817997
- Subjects
LYMPHADENITIS; CASTLEMAN'S disease; FLUORODEOXYGLUCOSE F18; TREATMENT effectiveness; COMPUTED tomography; POSITRON emission tomography computed tomography; INTERLEUKIN-6
- Publication
Insights into Imaging, 2021, Vol 12, Issue 1, p1
- ISSN
1869-4101
- Publication type
Article
- DOI
10.1186/s13244-021-00963-1